AI-powered Clinical Reasoning Engine aims to eliminate treatment delays and streamline healthcare workflows from diagnosis to therapy
Latent has announced the successful close of an $80 million Series A funding round, marking a significant milestone in its mission to transform how patients access life-saving therapies. The round was co-led by Spark Capital and Transformation Capital, with participation from Conviction, McKesson Ventures, General Catalyst, and Y Combinator. This infusion of capital is expected to accelerate the company’s efforts to bridge one of the most persistent and critical gaps in healthcare: the disconnect between clinical diagnosis and the actual delivery of treatment.
Despite decades of medical innovation, the infrastructure responsible for delivering care has struggled to keep pace with advances in diagnostics and therapeutics. In the United States, it is not uncommon for a patient and physician to arrive at a clear diagnosis and agree on an appropriate treatment plan, only to encounter significant delays—or outright denials—before therapy can begin. According to industry data, approximately 42% of critical cases experience such disruptions, even when the prescribed medication is readily available and clinically appropriate.
The root cause of this issue does not lie in the absence of effective treatments or poor clinical decision-making. Instead, it stems from the complex, fragmented processes that govern how therapies are approved, documented, and delivered. Every prescribed treatment must navigate a labyrinth of administrative requirements, including clinical documentation, payer authorization protocols, and pharmacy coordination. These processes are essential for ensuring safety, compliance, and cost control, but they are often executed through outdated, manual workflows that introduce inefficiencies and delays.
Currently, much of this work is performed by highly trained professionals operating across disconnected systems. Clinicians must switch between electronic health records (EHRs), payer portals, and internal tools to compile and submit documentation. Pharmacy teams frequently re-enter data that already exists in other systems, while administrative staff spend hours on phone calls and appeals to verify information that is already documented in patient records. This labor-intensive approach not only slows down care delivery but also contributes to clinician burnout and increases the risk of errors.
What makes this challenge particularly complex is that it is not merely administrative—it is deeply clinical in nature. Determining whether a patient qualifies for a specific therapy often requires interpreting lab results, understanding disease progression, and applying nuanced treatment criteria. This type of knowledge work has historically been difficult to automate, as it involves both structured and unstructured data, as well as context-dependent decision-making.
For the first time, advances in artificial intelligence are making it possible to address this challenge at scale. Latent is at the forefront of this transformation with its flagship innovation: the Clinical Reasoning Engine. This AI-powered system is designed to perform the kinds of high-stakes, knowledge-intensive tasks that have traditionally required human expertise, effectively bridging the gap between clinical intent and operational execution.
The Clinical Reasoning Engine operates by ingesting and analyzing patient data from multiple sources, including EHRs, laboratory systems, and clinical notes. It then applies relevant treatment criteria and payer guidelines to determine eligibility for specific therapies. By extracting key pieces of evidence and organizing them into structured formats, the system can automatically generate the documentation required for prior authorization and other approval processes.
Beyond documentation, the platform orchestrates workflows across the entire care continuum. It connects healthcare providers, insurance payers, pharmacies, and patients within a unified system, enabling seamless coordination and communication. Tasks that once required multiple handoffs and manual interventions can now be executed in real time by AI agents, significantly reducing delays and improving efficiency.
Latent initially focused on prior authorization, one of the most challenging and impactful bottlenecks in healthcare delivery. This process often determines whether a patient can access a prescribed therapy and is characterized by high complexity, strict regulatory requirements, and significant administrative burden. By successfully automating prior authorization workflows, Latent demonstrated the viability of its approach in one of the most demanding use cases in healthcare.
Building on this foundation, the company is now expanding its platform to address a broader range of clinical workflows. The goal is to create a comprehensive system that can translate clinical knowledge into action across every stage of the patient journey—from diagnosis and treatment selection to therapy initiation and ongoing management.
The impact of this approach is already evident. Latent currently works with approximately 50% of the top 20 health systems in the United States, including prominent organizations such as Yale New Haven Health, Ochsner Health, MetroHealth, UCI Health, Vanderbilt Health, Mount Sinai Health System, Henry Ford Health System, UCSF Health, and UCLA Health. Over the past year alone, the company has scaled rapidly, increasing its number of health system partners from just four to more than 45.
Through these partnerships, Latent is helping more than 2 million patients each year gain faster access to critical medications. The platform has been shown to reduce treatment denials by over 30% across a wide range of specialties and therapeutic areas. At the same time, it enables clinicians to serve significantly more patients by reducing the time spent on administrative tasks, effectively doubling their capacity in some cases.
Looking ahead, Latent envisions an even more proactive role for its Clinical Reasoning Engine. Rather than simply responding to treatment decisions, the system could identify patients who would benefit from specific therapies before they are prescribed, ensuring that care is both timely and appropriate. It could also monitor patient adherence and outcomes, helping to ensure that once therapy begins, it continues effectively.
This forward-looking approach reflects a broader ambition: to build the underlying infrastructure that connects clinicians, patients, payers, and pharmacies in a cohesive, intelligent ecosystem. By powering the knowledge work that determines what care patients ultimately receive, Latent aims to fundamentally reshape how healthcare is delivered.
The newly secured funding will play a critical role in advancing this vision. Latent plans to use the capital to expand its footprint across additional health systems, deepen integrations with existing partners, and enhance the capabilities of its platform. This includes continued investment in the reliability, accuracy, and trustworthiness of its AI systems—an essential requirement for operating in highly regulated healthcare environments.
In addition, the company intends to scale its team, attracting top talent across engineering, clinical, and operational domains. As the complexity of healthcare systems continues to grow, building a multidisciplinary team will be key to developing solutions that are both technically robust and clinically effective.
Ultimately, Latent’s mission extends beyond technological innovation. Latent is rooted in a fundamental belief that responsibility in healthcare does not end with diagnosis. Ensuring that patients actually receive the treatments they need—and do so in a timely and efficient manner—is an equally critical component of care.
By addressing the systemic barriers that stand between clinical decisions and therapeutic outcomes, Latent is positioning itself as a key player in the next wave of healthcare transformation. As adoption of its platform continues to grow, the company has the potential to redefine standards for efficiency, accessibility, and quality in patient care, bringing the industry closer to a future where life-saving treatments are delivered without unnecessary delay.
Source link: https://www.businesswire.com
